SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer

The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-week...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Clamp, A R, Mäenpää, J, Cruickshank, D, Ledermann, J, Wilkinson, P M, Welch, R, Chan, S, Vasey, P, Sorbe, B, Hindley, A, Jayson, G C
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2006
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361090/
https://ncbi.nlm.nih.gov/pubmed/16404360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602910
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki